---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-145685"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2021-12-02T23:59:59+00:00"
generated_at: "2026-06-28T04:04:56.026834+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties

## Summary
- Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.
- Royalties: 50% of U.S. net sales until earlier of Jan 1, 2025 or milestone paid, then 30%; 15% on ex-U.S. net sales.
- Transaction valued in excess of $1 billion including royalties; Omeros retains $34M accounts receivable.
- Omeros to focus on complement franchise of MASP-2 and MASP-3 inhibitors.
- Closing expected on or before Dec 31, 2021, subject to HSR waiting period expiration.

## SEC filing metadata
- accession: 0001104659-21-145685
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2021-12-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000110465921145685/0001104659-21-145685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000110465921145685/tm2134414d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-145685
- JSON: https://secwatch.observer/filing/0001104659-21-145685.json
- Plain text: https://secwatch.observer/filing/0001104659-21-145685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.